HELLS, helicase, lymphoid specific, 3070

N. diseases: 84; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 AlteredExpression group BEFREE GSCs preferentially expressed HELLS compared with their differentiated tumor progeny and nonmalignant brain cells. 30779712 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 Biomarker group BEFREE Conclusion: Our data reveal that HELLS is a key epigenetic driver of HCC; by altering the nucleosome occupancy at the NFR and enhancer, HELLS epigenetically suppresses multiple tumor suppressor genes to promote HCC progression. 30516846 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 Biomarker group BEFREE In conclusion, LSH promotes tumor growth of HCC through transcriptional regulation of CENPF expression. 31066149 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 Biomarker group BEFREE Cell proliferation assay, cell migration and invasion assays, plate colony formation assay, immunofluorescence assay, Operetta® high-content screening and analysis, Western blot analysis and Co-Immunoprecipitation (Co-IP) assay, RNA immunoprecipitation assay and tumor growth assay was used to address the potential interplay of between GINS4 and LSH, and the functional of GINS4. 31253190 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 AlteredExpression group BEFREE Ectopic expression of LSH promoted tumor formation. 28042322 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 Biomarker group BEFREE Significant trends were found between expression levels of FOXM1, CEP55, and HELLS and tumor staging. 22109759 2011
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.070 GeneticVariation group BEFREE DNA-binding surface regions (L2, L3 and the LSH motif) and conserved regions (II-V), had significantly poorer prognoses than tumors with mutations outside of those regions. 12509970 2003